Due to COVID-19 pandemic and the recent announcement of the French government of a second national lockdown, we have activated our business continuity plan and we have deployed our 100% remote-work model. Our team have the necessary resources available to do their jobs effectively from home and thus, we will continue to operate at full capacity.
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26-29 October 2020
- Updated guidance on pharmacovigilance procedures